1. |
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
- Ind, PW, et al.
(författare)
-
Adjustable maintenance dosing with budesonide/formoterol (Symbicort) reduces treatment costs in asthma
- 2004
-
Ingår i: International journal of clinical practice (Esher). - 1368-5031 .- 1742-1241. ; 58:s141, s. 33-41
-
Tidskriftsartikel (refereegranskat)abstract
- Adjustable maintenance dosing permits patients to increase or decrease their medication, according to a management plan, in response to daily variations in asthma. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler was compared with fixed dosing bid in eight randomised, open-label studies. Data on resource utilisation were collected prospectively in six of the studies. Duration of randomised treatment was 3 months (UK, Italy, Germany), 4 months (Belgium), 5 months (Canada) or 6 months (Sweden). Mean number of budesonide/formoterol inhalations/day was significantly lower for adjustable maintenance dosing vs. fixed dosing, which resulted in significantly lower drug and total costs with adjustable maintenance dosing vs. fixed-dosing group. In the 3- and 4-month studies, both regimens had similar effectiveness. In the Canadian and Swedish studies, a significantly lower percentage of adjustable maintenance dosing patients had asthma exacerbations compared with fixed dosing. Adjustable maintenance dosing reduced treatment costs, providing similar or better asthma control at a lower overall dose, compared with fixed dosing.
|
|
8. |
|
|
9. |
|
|
10. |
|
|
11. |
|
|
12. |
- Zabel, M, et al.
(författare)
-
Corrigendum
- 2019
-
Ingår i: ESC heart failure. - : Wiley. - 2055-5822. ; 6:4, s. 899-899
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
13. |
|
|